Analyst consensus rating
Filana Therapeutics Analyst Rating: none
FLNA is rated none by 2 analysts with a $6.50 target. As of 2026-08-25.
Direct answer
Filana Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.50.
Forecast evidence checked August 25, 2026.
Get free Filana Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.95
- Average price target
- $6.50
- High price target
- $8.00
- Low price target
- $5.00
- Low target gap
- +427%
- Target upside
- +585.1%
- High target gap
- +743.2%
- Target range width
- 316.2%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Filana Therapeutics?
Filana Therapeutics has a verified none consensus. The same dataset has an average price target of $6.50.
How far are Filana Therapeutics's low and high targets from the recorded price?
The low target implies +427%, while the high target implies +743.2%.
How many analysts are included in Filana Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Filana Therapeutics's target upside or downside calculated?
The average target of $6.50 is divided by the recorded price of $0.95, then one is subtracted to produce +585.1%. This does not guarantee a future return.
When was Filana Therapeutics's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.